These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 35649958)

  • 1. Mesenchymal stromal cell therapy for acute respiratory distress syndrome due to coronavirus disease 2019.
    Whittaker Brown SA; Iancu-Rubin C; Aboelela A; Abrahams A; Burke E; Drummond T; Grossman F; Itescu S; Lagdameo J; Lin JY; Mark A; Levine JE; Osman K
    Cytotherapy; 2022 Aug; 24(8):835-840. PubMed ID: 35649958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial.
    Payares-Herrera C; Martínez-Muñoz ME; Vallhonrat IL; de Molina RM; Torres MP; Trisan A; de Diego IS; Alonso R; Zafra R; Donaire T; Sánchez R; Rubio JJ; Duarte Palomino RF; Solá CA
    Trials; 2021 Jan; 22(1):9. PubMed ID: 33407777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series.
    Hashemian SR; Aliannejad R; Zarrabi M; Soleimani M; Vosough M; Hosseini SE; Hossieni H; Keshel SH; Naderpour Z; Hajizadeh-Saffar E; Shajareh E; Jamaati H; Soufi-Zomorrod M; Khavandgar N; Alemi H; Karimi A; Pak N; Rouzbahani NH; Nouri M; Sorouri M; Kashani L; Madani H; Aghdami N; Vasei M; Baharvand H
    Stem Cell Res Ther; 2021 Jan; 12(1):91. PubMed ID: 33514427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone Marrow-Derived Mesenchymal Stromal Cell Therapy in Severe COVID-19: Preliminary Results of a Phase I/II Clinical Trial.
    Grégoire C; Layios N; Lambermont B; Lechanteur C; Briquet A; Bettonville V; Baudoux E; Thys M; Dardenne N; Misset B; Beguin Y
    Front Immunol; 2022; 13():932360. PubMed ID: 35860245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigational Use of Mesenchymal Stem/Stromal Cells and Their Secretome as Add-On Therapy in Severe Respiratory Virus Infections: Challenges and Perspectives.
    Mattoli S; Schmidt M
    Adv Ther; 2023 Jun; 40(6):2626-2692. PubMed ID: 37069355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration in COVID-19 (REALIST-COVID-19): A structured summary of a study protocol for a randomised, controlled trial.
    Gorman E; Shankar-Hari M; Hopkins P; Tunnicliffe WS; Perkins GD; Silversides J; McGuigan P; Jackson C; Boyle R; McFerran J; McDowell C; Campbell C; McFarland M; Smythe J; Thompson J; Williams B; Curley G; Laffey JG; Clarke M; O'Kane C; McAuley DF
    Trials; 2020 Jun; 21(1):462. PubMed ID: 32493473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential application of mesenchymal stromal cells as a new therapeutic approach in acute respiratory distress syndrome and pulmonary fibrosis.
    Gazzaniga G; Voltini M; Carletti A; Lenta E; Meloni F; Briganti DF; Avanzini MA; Comoli P; Belliato M
    Respir Res; 2024 Apr; 25(1):170. PubMed ID: 38637860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial.
    Wilson JG; Liu KD; Zhuo H; Caballero L; McMillan M; Fang X; Cosgrove K; Vojnik R; Calfee CS; Lee JW; Rogers AJ; Levitt J; Wiener-Kronish J; Bajwa EK; Leavitt A; McKenna D; Thompson BT; Matthay MA
    Lancet Respir Med; 2015 Jan; 3(1):24-32. PubMed ID: 25529339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human placenta-derived mesenchymal stem cells transplantation in patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 (phase I clinical trial): safety profile assessment.
    Aghayan HR; Salimian F; Abedini A; Fattah Ghazi S; Yunesian M; Alavi-Moghadam S; Makarem J; Majidzadeh-A K; Hatamkhani A; Moghri M; Danesh A; Haddad-Marandi MR; Sanati H; Abbasvandi F; Arjmand B; Azimi P; Ghavamzadeh A; Sarrami-Forooshani R
    Stem Cell Res Ther; 2022 Jul; 13(1):365. PubMed ID: 35902979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mesenchymal stromal cells for acute respiratory distress syndrome (ARDS), sepsis, and COVID-19 infection: optimizing the therapeutic potential.
    Gorman E; Millar J; McAuley D; O'Kane C
    Expert Rev Respir Med; 2021 Mar; 15(3):301-324. PubMed ID: 33172313
    [No Abstract]   [Full Text] [Related]  

  • 11. Mesenchymal stromal cells as treatment for acute respiratory distress syndrome. Case Reports following hematopoietic cell transplantation and a review.
    Sadeghi B; Ringdén O; Gustafsson B; Castegren M
    Front Immunol; 2022; 13():963445. PubMed ID: 36426365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mesenchymal stromal/stem cells (MSCs) and MSC-derived extracellular vesicles in COVID-19-induced ARDS: Mechanisms of action, research progress, challenges, and opportunities.
    Moradinasab S; Pourbagheri-Sigaroodi A; Zafari P; Ghaffari SH; Bashash D
    Int Immunopharmacol; 2021 Aug; 97():107694. PubMed ID: 33932694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Randomized Trial of Mesenchymal Stromal Cells for Moderate to Severe Acute Respiratory Distress Syndrome from COVID-19.
    Bowdish ME; Barkauskas CE; Overbey JR; Gottlieb RL; Osman K; Duggal A; Marks ME; Hupf J; Fernandes E; Leshnower BG; Golob JL; Iribarne A; Rassias AJ; Moquete EG; O'Sullivan K; Chang HL; Williams JB; Parnia S; Patel NC; Desai ND; Vekstein AM; Hollister BA; Possemato T; Romero C; Hou PC; Burke E; Hayes J; Grossman F; Itescu S; Gillinov M; Pagani FD; O'Gara PT; Mack MJ; Smith PK; Bagiella E; Moskowitz AJ; Gelijns AC
    Am J Respir Crit Care Med; 2023 Feb; 207(3):261-270. PubMed ID: 36099435
    [No Abstract]   [Full Text] [Related]  

  • 14. Allogenic mesenchymal stromal cells and their extracellular vesicles in COVID-19 induced ARDS: a randomized controlled trial.
    Zarrabi M; Shahrbaf MA; Nouri M; Shekari F; Hosseini SE; Hashemian SR; Aliannejad R; Jamaati H; Khavandgar N; Alemi H; Madani H; Nazari A; Amini A; Hassani SN; Abbasi F; Jarooghi N; Fallah N; Taghiyar L; Ganjibakhsh M; Hajizadeh-Saffar E; Vosough M; Baharvand H
    Stem Cell Res Ther; 2023 Jun; 14(1):169. PubMed ID: 37365605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial.
    Matthay MA; Calfee CS; Zhuo H; Thompson BT; Wilson JG; Levitt JE; Rogers AJ; Gotts JE; Wiener-Kronish JP; Bajwa EK; Donahoe MP; McVerry BJ; Ortiz LA; Exline M; Christman JW; Abbott J; Delucchi KL; Caballero L; McMillan M; McKenna DH; Liu KD
    Lancet Respir Med; 2019 Feb; 7(2):154-162. PubMed ID: 30455077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility Study of Cord Tissue Derived Mesenchymal Stromal Cells in COVID-19-Related Acute Respiratory Distress Syndrome.
    Shaz BH; Kraft BD; Troy JD; Poehlein E; Chen L; Cheatham L; Manyara R; Hanafy K; Brown L; Scott M; Palumbo R; Vrionis F; Kurtzberg J
    Stem Cells Transl Med; 2023 Apr; 12(4):185-193. PubMed ID: 36929827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mesenchymal Stem Cell-Based Therapy as an Alternative to the Treatment of Acute Respiratory Distress Syndrome: Current Evidence and Future Perspectives.
    Fernández-Francos S; Eiro N; González-Galiano N; Vizoso FJ
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific Clinical and Immunological Changes Following Mesenchymal Stem Cell Transplantation in COVID-19-induced Acute Respiratory Distress Syndrome Patients: A Phase-I Clinical Trial.
    Kaffash Farkhad N; Sedaghat A; Reihani H; Adhami Moghadam A; Bagheri Moghadam A; Khadem Ghaebi N; Khodadoust MA; Nikpoor AR; Tavakol Afshari J
    Iran J Allergy Asthma Immunol; 2022 Dec; 21(6):687-703. PubMed ID: 36640060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mesenchymal Stem Cell Therapy for Severe COVID-19 ARDS.
    Häberle H; Magunia H; Lang P; Gloeckner H; Körner A; Koeppen M; Backchoul T; Malek N; Handgretinger R; Rosenberger P; Mirakaj V
    J Intensive Care Med; 2021 Jun; 36(6):681-688. PubMed ID: 33663244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mesenchymal stromal cell therapy for COVID-19 acute respiratory distress syndrome: a double-blind randomised controlled trial.
    Martínez-Muñoz ME; Payares-Herrera C; Lipperheide I; Malo de Molina R; Salcedo I; Alonso R; Martín-Donaire T; Sánchez R; Zafra R; García-Berciano M; Trisán-Alonso A; Pérez-Torres M; Ramos-Martínez A; Ussetti P; Rubio JJ; Avendaño-Solà C; Duarte RF
    Bone Marrow Transplant; 2024 Jun; 59(6):777-784. PubMed ID: 38409332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.